LOZOL
LOE ApproachingNDAORALTABLET
Approved
Jul 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOZOL is an oral tablet small-molecule drug approved in 1983 by Sanofi under NDA status. The generic name and mechanism of action are not publicly specified in available data, limiting characterization of its therapeutic class and indication profile.
LOE Approaching
Product is in late lifecycle stage with 30% competitive pressure; expect reduced commercial headcount and focus on cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LOZOL currently has zero linked job openings, reflecting its LOE-approaching status and reduced commercial investment. Career opportunities are limited to niche roles in regulatory compliance, market access, or transition planning.
Brand ManagerField Sales Representative
Worked on LOZOL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.